# Estrella Immunopharma Adds Fifth Site for Lymphoma Cell Therapy Trial

- URL: https://stocks.freetheai.org/news/estrella-immunopharma-adds-fifth-site-for-lymphoma-cell-therapy-trial-a17d34
- Published: 2026-10-14T20:15:00Z
- Category: company_news; sentiment: bullish; impact: low
- Symbols: [NASDAQ:ESLA](https://stocks.freetheai.org/symbols/NASDAQ-ESLA)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Estrella Immunopharma, Inc. (NASDAQ:ESLA) has activated Intermountain Health LDS Hospital in Salt Lake City, Utah, as the fifth clinical location for its ongoing STARLIGHT-1 Phase I/II trial. The study tests the company's investigational cell therapy, EB103, in adult patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The new facility will begin screening and enrolling trial participants after completing initial setup steps.

The expansion supports the trial's open-label dose-expansion phase, which tests the safety and effectiveness of EB103 at its recommended Phase II dose. EB103 utilizes licensed ARTEMIS technology to target CD19 proteins on cancer cells, operating through a cellular mechanism designed to mimic natural T-cell receptors. Data gathered across the five active clinical centers will directly shape the company's strategy for a future pivotal clinical study.

Investors and patient communities will watch for patient enrollment progress across the active study sites, which also include UC Davis Comprehensive Cancer Center, Baylor Scott & White Research Institute, Oregon Health & Science University, and University Hospitals Cleveland Medical Center. Further updates on trial data and clinical timeline milestones will indicate how effectively the treatment progresses toward pivotal evaluation.

## Key points

- Estrella Immunopharma activated Intermountain Health LDS Hospital as the fifth site for its STARLIGHT-1 Phase I/II trial.
- The trial evaluates EB103, a CD19-targeted T-cell therapy, for treating relapsed or refractory B-cell non-Hodgkin's lymphoma.
- The new Utah location will begin patient screening and enrollment once site initiation activities finish.
- Findings from the trial's dose-expansion cohort will help determine the company's strategy for a future pivotal trial.

## Questions and answers

### What is the STARLIGHT-1 trial evaluating?

The Phase I/II trial evaluates EB103, an investigational CD19-targeted T-cell therapy, in adult patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

### Where are the active clinical sites for Estrella's STARLIGHT-1 trial?

Active trial sites include UC Davis Comprehensive Cancer Center, Baylor Scott & White Research Institute, Oregon Health & Science University, University Hospitals Cleveland Medical Center, and Intermountain Health LDS Hospital.

### How does EB103 differ from traditional CAR-T cell therapies?

EB103 uses ARTEMIS technology to activate and regulate T cells through a mechanism that more closely resembles natural T-cell receptors when binding to CD19 cancer targets.